Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Starting in 2014, large phase III clinical trials began to disclose the study results of using programmed death (PD)-1 immune checkpoint inhibitors (ICIs) (pembrolizumab, nivolumab) and PD-ligand (L)1 (atezolizumab, durvalumab, avelumab) ICIs immunotherapy in patients with advanced head and neck squ...

Full description

Bibliographic Details
Main Author: Victor C. Kok
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
PD-1/PD-L1 signaling pathway
HNSCC
immune checkpoint blockade
cancer immunotherapy
innate resistance
adapted resistance
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00268/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00268/full

Similar Items